Systematic Evaluation of Traditional Chinese Medicine Combined with Zoledronic Acid Treatment for Lung Cancer with Bone Metastasis / 世界科学技术-中医药现代化

ABSTRACT

Objective: To prove the effect and decrease toxicity in the treatment of lung cancer with bone metastasis of Traditional Chinese medicine and provide service for clinical by comparing the efficacy of traditional Chinese medicine combined with zoledronic acid with pure zoledronic acid in the treatment of lung cancer with bone metastasis. Methods: A retrieval was made for randomized controlled trials of traditional Chinese medicine combined with zoledronic acid in the treatment of lung cancer with bone metastasis which have been included in CNKI, VIP, Wanfang, PubMed, EMbase and CMB to March, 2018, and meta-analysis was performed according to Cochran systematic evaluation method and Revman 5.0. Results: A total of 14 RCTs and 847 patients were included. Compared with control group, ache in the Traditional Chinese medicine combined with zoledronic acid group remarkably decreased (RR =1.50, 95％CI =1.35-1.68, P ＜ 0.000 01), while the living quality remarkably increased (RR =1.47, 95％CI =1.27-1.70, P ＜ 0.000 01), and there were significant role and advantages in improving TCM syndromes of patients (RR =5.69, 95％CI =2.26-14.34, P =0.000 2), prolonging TTP (MD =1.16, 95％CI =0.74-1.58, P ＜ 0.000 01), decreasing serum calcium (MD =-0.32, 95％CI =-0.46——0.17, P ＜ 0.000 1) and reducing adverse reactions (RR =0.51, 95％CI =0.32-0.81, P =0.005). Conclusion: Traditional Chinese medicine combined with zoledronic acid has remarkable curative efficacy and safety in the treatment of lung cancer with bone metastasis, and it may be widely used in clinical practice.